Literature DB >> 15946129

Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression.

Ximin Lin1, Noah J Robinson, Mark Thursz, Daniel M Rosenberg, Andrew Weild, Jeanne M Pimenta, Andrew J Hall.   

Abstract

Countries in the the Asia-Pacific region and Africa tend to have the highest prevalence of hepatitis B infection worldwide. Hepatitis B infection progresses from an asymptomatic persistently infected status to chronic hepatitis B, cirrhosis, decompensated liver disease and/or hepatocellular carcinoma. The aim of this review was to summarize rates and risk factors for progression between disease states in the Asia-Pacific region and Africa. A literature search was conducted employing MEDLINE and EMBASE (1975-2003) using the following key words: hepatitis B, natural history, disease progression, cirrhosis, hepatocellular carcinoma, mortality, Africa and the Asia-Pacific region. Bibliographies of articles reviewed were also searched. Ranges for annual progression rates were: (i) asymptomatic persistent infection to chronic hepatitis B, 0.84-2.7%; (ii) chronic hepatitis B to cirrhosis, 1.0-2.4%; and (iii) cirrhosis to hepatocellular carcinoma, 3.0-6.6%. Patients with asymptomatic persistent infection and chronic hepatitis B had relatively low 5-year mortality rates (<4%); rates (>50%) were much higher in patients with decompensated liver disease and hepatocellular carcinoma. No data were found for progression rates in African populations. Hepatitis B e antigen was a risk factor for chronic hepatitis B, and bridging hepatic necrosis in chronic hepatitis B increased the risk of cirrhosis. Risk factors for hepatocellular carcinoma included cirrhosis, co-infection with hepatitis C virus, and genetic and environmental factors. In this review, wide ranges of disease progression estimates are documented, emphasizing the need for further studies, particularly in Africa, where progression rates are largely not available. Summarizing information on factors associated with disease progression should assist in focusing efforts to arrest the disease process in those at most risk. (c) 2005 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 15946129     DOI: 10.1111/j.1440-1746.2005.03813.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  26 in total

1.  Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study.

Authors:  George Boon-Bee Goh; Wan-Cheng Chow; Renwei Wang; Jian-Min Yuan; Woon-Puay Koh
Journal:  Hepatology       Date:  2014-06-24       Impact factor: 17.425

2.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

3.  Too much of a good thing? When to stop catch-up vaccination.

Authors:  David W Hutton; Margaret L Brandeau
Journal:  Med Decis Making       Date:  2013-07-15       Impact factor: 2.583

4.  Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China.

Authors:  David W Hutton; Samuel K So; Margaret L Brandeau
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

5.  Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves.

Authors:  Sun-Young Kim; Joshua A Salomon; Sue J Goldie
Journal:  Bull World Health Organ       Date:  2007-11       Impact factor: 9.408

6.  Management of chronic hepatitis B: consensus guidelines.

Authors:  Morris Sherman; Stephen Shafran; Kelly Burak; Karen Doucette; Winnie Wong; Nigel Girgrah; Eric Yoshida; Eberhard Renner; Philip Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

7.  Hepatocellular carcinoma in patients with autoimmune hepatitis.

Authors:  Andreas Teufel; Arndt Weinmann; Catherine Centner; Anja Piendl; Ansgar W Lohse; Peter R Galle; Stephan Kanzler
Journal:  World J Gastroenterol       Date:  2009-02-07       Impact factor: 5.742

8.  Treatment of hepatitis B in decompensated liver cirrhosis.

Authors:  Richard Guan; Hock Foong Lui
Journal:  Int J Hepatol       Date:  2011-06-23

9.  Inducible viral receptor, A possible concept to induce viral protection in primitive immune animals.

Authors:  Tirasak Pasharawipas
Journal:  Virol J       Date:  2011-06-28       Impact factor: 4.099

10.  Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges.

Authors:  Maud Lemoine; Shevanthi Nayagam; Mark Thursz
Journal:  Future Virol       Date:  2013-04       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.